查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
流感诊断市场规模、份额和成长分析（按产品、检测方法、最终用户和地区划分）—产业预测（2026-2033 年）
市场调查报告书
商品编码
1897653

流感诊断市场规模、份额和成长分析（按产品、检测方法、最终用户和地区划分）—产业预测（2026-2033 年）

Influenza Diagnostics Market Size, Share, and Growth Analysis, By Product (Test kit & Reagents, Instruments), By Test (Molecular Diagnostic Test, Transcription Mediated Amplification Based Assay), By End User, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到 2024 年，流感诊断市场规模将达到 11.4 亿美元，到 2025 年将达到 11.8 亿美元，到 2033 年将达到 15.5 亿美元，在预测期（2026-2033 年）内，复合年增长率为 3.5%。

世界人口老化加剧，医疗成本不断攀升，治疗方法也不断改进。为此，世界卫生组织（WHO）和美国疾病管制与预防中心（CDC）等监管机构正积极收集流感发病率和盛行率数据，以遏制流感蔓延。他们与地方政府合作，加强疾病防治和治疗。世界卫生组织全球流感规划等措施为应对各种流感病例提供技术援助和策略指导，预计将对流感诊断市场产生正面影响。然而，受新冠肺炎疫情影响，市场面临许多挑战，包括生产中断和影响诊断方法的监管变化。新冠肺炎与流感在症状表现上的通用，凸显了流感检测的重要性，并进一步推动了诊断领域的需求。

流感诊断市场驱动因素

全球流感发病率的不断上升显着推动了旨在提高检测和诊断方法准确性的研发活动。本研究重点关注快速、准确的流感病毒诊断工具的开发，这将反过来推动流感诊断市场的成长。此外，政府加强对抗疫情传播的措施以及技术的持续进步预计也将对市场扩张做出积极贡献。同时，心血管疾病和糖尿病盛行率的上升预计也将进一步支撑对高效流感诊断的需求，从而推动整体市场成长。

流感诊断市场的限制因素

流感诊断市场的发展面临许多挑战，包括熟练专业人员短缺和新诊断测试核准法规环境分散。合格人员的匮乏，加上医疗基础设施不足（尤其是在发展中地区），进一步加剧了市场格局的复杂性。这些因素不仅阻碍了诊断解决方案的有效应用，也减缓了创新和适应不断变化的医疗需求的速度。因此，解决这些结构性挑战对于营造有利于市场成长的环境、提高流感诊断的整体有效性至关重要。

流感诊断市场趋势

全球流感诊断市场呈现显着上升趋势，主要受流感病例报告激增以及人们对早期检测和预防重要性认识不断提高的推动。流感疫情的不断爆发凸显了对有效诊断解决方案的需求，促使医疗机构增加对先进检测方法的投资。此外，对疫情防范的日益重视以及强有力的医疗政策的实施也推动了市场需求。大众对流感相关健康影响的认识不断提高，使得创新诊断工具备受关注，为未来市场规模的显着扩张铺平了道路。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析和影响

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 技术进步
  • 监管环境
  • 案例研究
  • 专利分析

流感诊断市场规模（依产品划分）及复合年增长率（2026-2033 年）

  • 检测套组和试剂
  • 装置
  • 其他的

流感诊断市场规模（按检测类型和复合年增长率划分）（2026-2033 年）

  • 分子诊断检测
    • 聚合酵素链锁反应
    • 恒温核酸增幅检测
  • 基于转录媒介增幅的检测
  • 基于恒温环型核酸扩增的检测
  • 基于核酸序列的扩增试验
  • 常规诊断测试
  • 快速流感诊断测试
  • 病毒培养试验
  • 直接萤光
  • 血清学检测

流感诊断市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

  • 诊断实验室
  • 医院和诊所
  • 其他的

流感诊断市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2021-2023年营收年比比较

主要企业简介

  • Thermo Fisher Scientific（US）
  • Becton, Dickinson and Company（US）
  • F. Hoffmann-La Roche AG（Switzerland）
  • Hologic, Inc.（US）
  • Abbott Laboratories, Inc.（US）
  • DiaSorin（Italy）
  • QIAGEN NV（Netherlands）
  • Fujirebio Diagnostics, Inc.（Japan）
  • Meridian Bioscience, Inc.（US）
  • Luminex Corporation（US）
  • Seegene Inc.（South Korea）
  • Bio-Rad Laboratories, Inc.（US）
  • Alere Inc.（US）
  • GenMark Diagnostics, Inc.（US）
  • Roche Diagnostics（Switzerland）
  • BioMerieux SA（France）
  • Cepheid（US）
  • SD Biosensor（South Korea）
  • Acon Laboratories, Inc.（US）
  • Inverness Medical Innovations, Inc.（US）

结论与建议

简介目录
Product Code: SQSG35G2011

Influenza Diagnostics Market size was valued at USD 1.14 Billion in 2024 and is poised to grow from USD 1.18 Billion in 2025 to USD 1.55 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The growing healthcare expenditure and improved treatment options are contributing to an aging global population, prompting regulatory bodies like the WHO and CDC to diligently compile incidence and prevalence data to combat influenza. Collaborative efforts with local governments aim to enhance disease management and treatment. Initiatives such as the WHO's Global Influenza Program facilitate technical support and strategic guidance for addressing various influenza cases, which is expected to positively influence the Influenza Diagnostics market. However, the market has faced challenges due to the impact of COVID-19, including manufacturing disruptions and regulatory changes affecting diagnostic measures. The similarities between COVID-19 and influenza, particularly in symptomatic presentation, underscore the importance of influenza testing, further driving demand in the diagnostics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Influenza Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Influenza Diagnostics Market Segments Analysis

Global Influenza Diagnostics Market is segmented by Product, Test, End User and Region. Based on Product, the market is segmented into Test kit and Reagents, Instruments, Other Products. Based on Test, the market is segmented into Molecular Diagnostic Test (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification, Tests), Transcription Mediated Amplification Based Assay, Loop Mediated Isothermal Amplification Based Assay, Nucleic Acid Sequence based Amplification Tests, Traditional Diagnostics Tests (Rapid Influenza Diagnostic Test, Viral Culture Test, Direct Fluorescent Antibody Test, Serological Tests). Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals and Clinics, Others. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Influenza Diagnostics Market

The growing global incidence of influenza has significantly stimulated research and development efforts aimed at enhancing the accuracy of detection and diagnosis methods. A considerable focus within this research is directed towards creating rapid and precise diagnostic tools for influenza viruses, which will consequently propel the growth of the Influenza Diagnostics Market. Furthermore, increased government initiatives to combat outbreaks, coupled with ongoing technological advancements, will also contribute positively to market expansion. Additionally, the rising prevalence of cardiovascular diseases and diabetes is expected to further support the demand for effective influenza diagnostics and drive overall market growth.

Restraints in the Influenza Diagnostics Market

The growth of the Influenza Diagnostics market faces significant challenges due to the shortage of skilled professionals and an inconsistent regulatory environment for the approval of new diagnostic tests. This scarcity of qualified personnel, coupled with inadequate healthcare infrastructure, particularly in developing regions, further complicates the market landscape. These factors not only hinder the effective implementation of diagnostic solutions but also delay innovation and adaptation in response to evolving healthcare needs. As a result, addressing these systemic issues is crucial for fostering a conducive environment for growth and enhancing the overall efficacy of influenza diagnostics.

Market Trends of the Influenza Diagnostics Market

The global influenza diagnostics market is witnessing a notable upward trend driven by a surge in reported influenza cases and a heightened awareness surrounding the importance of early detection and prevention. The rise in influenza incidences highlights the critical need for effective diagnostic solutions, prompting healthcare providers to invest in advanced testing methodologies. Furthermore, the growing emphasis on epidemic preparedness and the implementation of robust healthcare policies are bolstering market demand. As the public becomes increasingly cognizant of the health implications associated with influenza, innovative diagnostic tools are gaining traction, paving the way for substantial market expansion in the foreseeable future.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Driver & Opportunities
    • Restraints & Challenges
  • Porters Analysis & Impact
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technological Advancement
  • Regulatory Landscape
  • Case Studies
  • Patent Analysis

Influenza Diagnostics Market Size by Product & CAGR (2026-2033)

  • Market Overview
  • Test kit and Reagents
  • Instruments
  • Others

Influenza Diagnostics Market Size by Test & CAGR (2026-2033)

  • Market Overview
  • Molecular Diagnostic Test
    • Polymerase Chain Reaction
    • Isothermal Nucleic Acid Amplification
    • Tests
  • Transcription Mediated Amplification Based Assay
  • Loop Mediated Isothermal Amplification Based Assay
  • Nucleic Acid Sequence based Amplification Tests
  • Traditional Diagnostics Tests
  • Rapid Influenza Diagnostic Test
  • Viral Culture Test
  • Direct Fluorescent Antibody Test
  • Serological Test

Influenza Diagnostics Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Others

Influenza Diagnostics Market Size & CAGR (2026-2033)

  • North America, (Product, Test, End User)
    • US
    • Canada
  • Europe, (Product, Test, End User)
    • UK
    • Germany
    • Spain
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific, (Product, Test, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America, (Product, Test, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product, Test, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

  • Thermo Fisher Scientific (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hologic, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • DiaSorin (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN N.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fujirebio Diagnostics, Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Meridian Bioscience, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Luminex Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seegene Inc. (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alere Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GenMark Diagnostics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Diagnostics (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioMerieux SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cepheid (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SD Biosensor (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Acon Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Inverness Medical Innovations, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendation